Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
A First-in-Class MCL-1 degrader to promote apoptosis in therapy-resistant liquid and solid tumours (CT-03)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Poland
Call: EIC Accelerator Open 2024 (HORIZON-EIC-2024-ACCELERATOR-02, 2024)
Start date: 2026-01-01
End date: 2027-12-31
Duration (months): 24.0
Total project cost (EUR): 3571250.0
EU funding (EUR): 2499875.0
Participants: 1
Project status: SIGNED

Captor Therapeutics is a biopharmaceutical company pioneering the development of therapeutics for unmet medical needs using Targeted Protein Degradation. We focus on high-value drug targets that are “undruggable” by conventional approaches. One such target is MCL-1, a protein preventing programmed cell-death. MCL-1 is implicated in resistance to cancer treatments. Due to its broad applications, developing a safe therapy that could hamper MCL-1's effect in cancer cells, would be a gamechanger for oncology. Unfortunately, MCL-1 inhibitors give rise to cardiotoxicity, which has led to the termination of several clinical trials. Our unique TPD technology platform allows us to apply a radically different approach. We have developed a small molecule able to tag MCL-1 for degradation using the cellular waste protein disposal system. CT-03, positioned to become a First-in-Class MCL-1 degrader, has shown potent degradation, with no signs of cardiotoxicity in Cynomolgus monkeys, the closest translational bridge to humans. Our first indication – AML (Acute Myeloid Leukaemia) – has a market size of €3.6bn. Currently, Venclexta is commonly used in AML patients unable to undergo ablative chemotherapy or hematopoietic stem cell transplantation. Unfortunately, nearly all AML patients eventually acquire resistance to Venclexta, which leaves them with no further treatment options. By degrading MCL-1, CT-03 will make resistant cells susceptible to conventional therapies again. The project’s goal is to demonstrate safety and lack of cardiotoxicity in humans. Successful results from a Phase Ia/Ib trial on Venclexta-resistant AML patients will constitute a crucial inflection point for securing a lucrative out-licensing deal with a large pharmaceutical company. Our future partner will take CT-03 forward in AML and other poorly-treated cancers. Revenues from the out-licensing deal will be invested into advancing our clinical pipeline of protein degraders in oncology & neurodegeneration.

Keywords: mcl 1,bifunctional degrader,targeted protein degradation,haematological cancers,resistance to cancer therapy,venetoclax,acute myeloid leukemia
NEW CLASS OF CANCER VACCINES BASED ON THE PROPRIETARY ANTIGEN-PRESENTING CELL LINE (PDC*LINE) (PDCline)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Belgium
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

PDC*line Pharma is a clinical-stage biotechnology company that develops a new class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary Plasmacytoid Dendritic Cells (PDC*line) cell line. It is the only cell line of ready-to-use Dendritic Cells for therapeutic use. It is loaded with synthetic peptides derived from tumor antigens, irradiated to stop the proliferation of the cells, and can be stored frozen for years. After thawing, it is injected to activate in vivo a potent cytotoxic anti-tumor CD8+ T-cell response. This proprietary PDC*line is very easy to expand, is more potent than conventional Dendritic Cells, and is a versatile platform broadly applicable to any cancer. Our product comes in the form of five pipelines, yet considering the potential of the non-small cell lung cancer market and the resources required to address this opportunity, we will primarily focus on the development of our lead asset PDC*lung. By bringing our technology to the market, we will address the shortcomings of current cancer vaccines. Existing DC-based vaccines have shown safety but limited clinical success. The search for an optimal combination of immunotherapeutics and cancer vaccines continues and we have shown the promise of our solution in the interim analysis of a Phase I/II clinical trial. Bringing our PDC*lung product through clinical efficacy validation will greatly impact the company's growth and allow it to scale. Our vision encompasses a future where PDC*line immunotherapies become a cornerstone in the global fight against cancer, bringing about a paradigm shift in treatment approaches.

Keywords: immunotherapy,lung cancer,dendritic cells,therapeutic cancer vaccines,off the shelf,proprietary cell line
Next-Generation Molecular Diagnostics Platform Enabling Immediate and Ultra-Sensitive Detection of STDs at the Point of Care (Sherman DX)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Affecting over 17M people in Europe and 365M globally each year, Sexually Transmitted Diseases (STDs) are among the most concerning infectious diseases due to their severe psychological, economic, and physical impacts. Just two pathogens account for nearly 60% of these cases: Chlamydia trachomatis (CT) accounts for 129M, while Neisseria gonorrhoeae (NG) affects 82M. A major limitation in controlling the spread of STDs is the lack of point-of-care diagnostic solutions that meet all WHO criteria, particularly to provide results within 15 minutes with high accuracy. Sherman Diagnostics is introducing a rapid, low-cost, and ultra-sensitive detection platform for diagnosing CT, NG, and antimicrobial-resistant variants at the point of care. Our proprietary “Spectral Photonic Modulation” (SPM) technology detects single target molecules in crude samples within seconds, eliminating the need for time-consuming and expensive PCR amplification. We have clinically validated our solution’s breakthrough performance with results demonstrating over 95% sensitivity, 95-100% specificity, and a limit of detection of fewer than 100 bacteria/ml. These results were obtained in a prospective clinical trial involving over 200 samples from patients at two hospitals. With a sample-to-result time of less than 2 minutes, our novel POC diagnostic tests will be pivotal in expanding screening and enhancing testing for people at high risk of STDs. We will thus enable widespread and easily accessible early and accurate diagnosis, which is critical for controlling the spread of the STD pandemic and providing patients with immediate, proper treatment. The EIC support will allow us to optimise our solution to detect AMR variants, validate it in a pivotal clinical trial, and obtain regulatory approval in Europe, leading to commercialisation. Our ambition is to reach over 4 million patients by 2031 and expand our diagnostic platform to other critical pathologies requiring rapid diagnosis, such as sepsis.

Keywords: sexually transmitted diseases infections,std,sti,std screening,sti screening,fluorescence microscopy,poc diagnostics,chlamydia trachomatis,neisseria gonorrhoeae,antimicrobial resistance
The I in Misinformation: Understanding the Role of Individual Behavior in Social Media Information Diffusion (URIBMD)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Germany
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2024-08-15
End date: 2026-08-14
Duration (months): 24.0
Total project cost (EUR): 189687.36
EU funding (EUR): 189687.36
Participants: 1
Project status: SIGNED

The diffusion of misinformation, propaganda, and conspiracy theories on social media are threating democratic values worldwide. Malevolent use of social media is not only eroding public trust in mainstream media but is also reducing citizens’ trust in democratic institutions. This decline in trust (and often in concert with unfounded claims) has led to protests and even violent rioting, illustrating a growing divide between citizens and their democratic institutions. Although several interdisciplinary solutions have been developed to gauge and control the cascade of misleading information, the threat persists and is only predicted to deteriorate. Previous research has pointed out that, thus far, little attention has been paid to the individuals’ behaviours when consuming news. In this interdisciplinary work, we set out to harness insights from emerging paradigms in cognitive science, social psychology, collective behaviour and computational social science to better understand the sociological, cultural, and psychological factors that influence individuals’ choices when consuming and sharing misinformation; and how these choices cascade throughout their social circles and communities. The project aims to gain insights into individuals’ online behaviour on three key dimensions, 1) visual attention, 2) conversational affordances, and 3) temporal information diffusion. By combining these insights with computational social science and statistical methods, and by applying them to large-scale digital trace data of EU citizens, we aim to provide new insights into the sociological and psychological factors that make individuals more susceptible to trusting misinformation. The project aims to contribute to the EU’s democracy plan of developing policies to defend EU citizens against misinformation, disinformation, and foreign interference.

Keywords: misinformation,social media,deliberation,human behaviour,digital trace data,visual attention
Bringing humanlike digital eyes to the world (SilRet)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: France
Call: EIC Accelerator 2024 - Short application (HORIZON-EIC-2024-ACCELERATOR-01, 2024)
Duration (months): 24.0
Total project cost (EUR): 2499999.0
EU funding (EUR): 2499999.0
Participants: 1
Project status: SIGNED

Welcome to the future of semiconductor image sensors. In an industry where innovation is constantly pushing boundaries, we are proud to introduce a game-changing technology that will revolutionize the market. Introducing the SilRet project, an unprecedented development of Complementary Metal Oxide Semiconductor (CMOS) sensor curving technology at industrial scale. Today, traditional flat CMOS image sensor technology have reached a plateau in image quality and resolution. Meanwhile, curved image sensors have been recognized as a natural solution to unlock those limitations while maintaining compactness crucial for applications ranging from compact devices to IoT devices (mobile, medical imaging, agriculture, automotive...). Image sensors can be curved to match the natural curvature of the lens, ensuring uniform focus across the sensor plane and significantly enhancing image quality without increasing the size or complexity of the camera system. While curving image sensors is not a novelty on its own, the industrialization of this process has always been a significant hurdle. That is until now. The SilRet project is already well on its way to overcoming this challenge by introducing a breakthrough and complete manufacturing solution capable of curving over 1000 sensors per hour. This scale of production aligns perfectly with expectations and demands of the market. The CMOS sensor market is on a steep growth trajectory, predicted to reach €31 billion by 2027. Moreover, the integration of these sensors into billions of devices annually highlights the vast potential of Silina's technology and business. Silina sets sight to achieve over 400M€ in sales by 2030 and with an organization of about 280 employees, committed to delivering excellence in every aspect of our operations. The SilRet project represents a significant leap forward in CMOS imaging sensor technology and Silina, a European company, will be the first to bring human-like digital eyes to the world.

Keywords: curved cmos sensors compact imaging industrial scale production innovative optical technology high image quality semiconductor solutions sensors
Transforming battery technology for energy storage with CarbonPlus (CarbonPlus)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Other destinations
Action type: EIC actions
Countries involved: Israel
Call: EIC Accelerator 2025 - Short application (HORIZON-EIC-2025-ACCELERATOR-01, 2025)
Duration (months): 24.0
Total project cost (EUR): 2500000.0
EU funding (EUR): 2500000.0
Participants: 1
Project status: SIGNED

Energy storage technologies are pivotal in accelerating the global transition to sustainable energy, supporting renewable sources like solar and wind, and driving the electrification of transport through electric vehicles (EVs). However, realizing the full potential of electrification requires overcoming significant technical, economic, and environmental challenges. Currently, lithium-ion (Li-ion) batteries dominate the energy storage market, valued for their ability to recharge repeatedly and provide a practical alternative to fossil fuel-based systems. Yet, Li-ion batteries have limitations, including high costs, finite cycle life, and substantial environmental impacts associated with the extraction and disposal of critical materials like lithium, cobalt, and nickel. EEXION introduces a groundbreaking energy storage solution, CarbonPlus, which features advanced carbon-based cathode materials designed to transform the energy storage landscape. CarbonPlus is a porous, chemically modified carbon material that serves as a high-efficiency, sustainable alternative to metal-based cathodes used in conventional Li-ion batteries. This innovation not only minimizes environmental impact but also reduces reliance on scarce and geopolitically sensitive metals, enhancing the sustainability and security of the supply chain. EEXION’s CarbonPlus technology offers remarkable advancements in energy density, achieving up to 200 Wh/kg, which is comparable to lithium iron phosphate (LFP) batteries. It also extends cycle life significantly, demonstrating minimal degradation over tens of thousands of charge cycles. This durability lowers the total cost of ownership, making energy storage solutions more cost-effective and accessible. Furthermore, CarbonPlus technology is highly versatile and adaptable, making it suitable for a wide range of applications, from energy storage to EVs and micro-mobility solutions.

Keywords: global energy storage,carbonplus technology,cathode,cost effecyive batteries,energy transition
Gates to Language (GALA)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Starting grants
Action type: ERC actions
Panel: The Human Mind and Its Compl exity
Panel description: Cognitive science, psychology, linguistics
Countries involved: Spain
Call: ERC STARTING GRANTS (ERC-2023-STG, 2023)
Start date: 2024-06-01
End date: 2029-05-31
Duration (months): 60.0
Total project cost (EUR): 1490057.99
EU funding (EUR): 1490057.99
Participants: 2
Project status: SIGNED

Language is perhaps the most prominent feature that distinguishes humans from the rest of the animal kingdom. Nevertheless, many perceptual and learning mechanisms serving language acquisition are not tailored specifically to language nor to humans. Decades of research have shown that several animal species are equipped with perceptual, cognitive and neural architectures that allow to learn language but only humans end up doing so. The key features and mechanisms that make language learnable by very young humans are still unclear. The GALA project focuses on how humans begin to learn language, exploring the biological nature of the mechanisms at the ‘entry-gate’ of language through a comparative-developmental approach involving nonhuman species, human newborns, infants and adults. Syllables are essential processing units of speech at the onset of language acquisition, through which newborns and infants preferentially encode and organize the speech signal. My proposal is that the mechanisms that allow to parse syllables from speech emerge from evolutionary-ancient sensory processes that likely evolved to compute different inputs in different species. I will explore two alleged universal linguistic constraints responsible for parsing syllables, and shaping the syllabic structure: Maximal Onset Principle (Research Line 1) and Sonority Hierarchy (Research Line 2). I will test such constraints across species, and at distinct stages of human development as well as in distinct sensory modalities, with behavioral and neuroimaging techniques. The GALA project will shed light on the ontogenetic and phylogenetic origins of the mechanisms through which humans access language, and will provide invaluable new knowledge that will bring us closer to understand why are humans the only species so far able to learn language.

Keywords: language learning,comparative cognition
Global Lingua Franca: A Transnational History of French, 1800–1870 (GoLingua)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Germany,France
Call: MSCA Postdoctoral Fellowships 2022 (HORIZON-MSCA-2022-PF-01, 2022)
Start date: 2023-10-01
End date: 2025-09-30
Duration (months): 24.0
Total project cost (EUR): 189687.36
EU funding (EUR): 189687.36
Participants: 2
Project status: CLOSED

GoLingua contrasts the French language’s relative decline across post-Napoleonic Europe against its prominence as a “Global Lingua Franca” among new elites who came increasingly in contact with European space from 1800 through 1870. By focusing on the outward spread of the language from Paris to the country’s modest empire, researchers have lost sight of the female speakers and isolated elites from many areas who adopted French to connect with a globalizing world. My research recovers the stories of non-native French speakers from many regions in order to propose a new transnational framework for the study of the history of language. Recent histories of global French begin their accounts in the final third of the nineteenth century, when the French colonial empire expanded beyond Algeria. I challenge this consensus by showing how speakers outside French space learned the language in a much earlier period. Shared communications in French created a long-lasting form of social cohesion that stretched across national and imperial borders. The project will lead to two peer-reviewed articles on the ways that various groups used French in three locations: Haiti, Germany, and Russia. My grant will give me new skills in the Russian language and quantitative discourse analysis, which will be applied to conduct research in German, French, Luxembourgish, and American archives. A secondment in France will allow me to attend French cultural events in Paris before returning to Trier to meet Institut Français officials working in Frankfurt and Luxembourg. A writing project developed out of these meetings will communicate the global significance of my research. By uncovering the polyvocal origins of global francophonie, I demonstrate the importance of multilingualism for a cosmopolitan European identity today.

Keywords: transnational french history global history history of germany,russia,and haiti french and francophone literature historical sociolinguistics
The First Miniaturized Non-Resonant Antenna Tailored to Internet of Things Applications (TRIO++)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Accelerator
Destination: Challenges
Action type: EIC actions
Countries involved: Spain
Call: EIC Accelerator Challenge: Technologies for Open Strategic Autonomy (HORIZON-EIC-2022-ACCELERATOR-01, 2022)
Start date: 2022-12-01
End date: 2024-11-30
Duration (months): 24.0
Total project cost (EUR): 2801525.0
EU funding (EUR): 1961067.0
Participants: 1
Project status: CLOSED

Our solution is a novel antenna technology (called ‘Virtual Antenna’) that our company has invented and patented (40+ patents granted). Due to its non-resonant nature, our antenna yields numerous benefits when designing Internet of Things (IoT) devices: – the ‘Virtual Antenna’ can work at any frequency (ranging from 400 MHz to 10.6 GHz) and with any protocol (Wi-Fi, GPS, 4G, 5G, Bluetooth, and more), thus providing design versatility and scalability; – the ‘Virtual Antenna’ fits on tiny devices because it is about 10 times smaller than state-of-the-art resonant antennas; – while the design process of standard antennas requires numerous physical prototypes, the electromagnetic behavior of the 'Virtual Antenna’ can be accurately simulated via software, thus leading to shorter and cheaper design processes; – while resonant antennas can be designed only by electromagnetic experts, any electrical engineer or technology-savvy has the knowledge to use the ‘Virtual Antenna’ in an IoT product.

Keywords: antennas